Medication info
Olmesartan Medoxomil/ S-Amlodipine Besylate 2.5 mg/40 mg

Olmesartan Medoxomil/ S-Amlodipine Besylate 2.5 mg/40 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletS-Amlodipine Besylate 2.5 Hydrate›3.74mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
Light yellow, round, film-coated tablet
Packaging
30 tablets
Approval status
Active

MFDS item code 201600297 · Approved 2016.01.15 · Insurance code 653403510

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (S-amlodipine (amlodipine) or olmesartan medoxomil) be adjusted. However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose with adequate monitoring of their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be considered. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Essential hypertension
View approved original text

This medication is primarily used for the treatment of essential hypertension. It is effective in cases where blood pressure is not well controlled with monotherapy of S-Amlodipine or Olmesartan Medoxomil. This helps to manage blood pressure reliably, reducing the risk of cardiovascular complications. It is adjusted appropriately according to the patient's blood pressure condition to assist in improving health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (S-amlodipine (amlodipine) or olmesartan medoxomil) be adjusted. However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose with adequate monitoring of their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be considered. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Individuals with known allergies to this medication or similar class of drugs, those who are pregnant or breastfeeding, those with severe liver dysfunction, severe heart valve disease, bile duct obstruction, those undergoing kidney dialysis, those in shock, some diabetic patients, and those with severely impaired kidney function should not take this medication. In patients with hypotension due to insufficient body fluids or sodium, careful monitoring is necessary at the beginning of treatment as blood pressure may drop too low, and appropriate measures should be taken if hypotension occurs. Acute hypotension may rarely occur due to vasodilatory effects, so patients with severe heart valve stenosis should exercise caution. Patients with ischemic heart disease or congestive heart failure may experience exacerbation of symptoms when taking this medication, and should use it cautiously. Patients with impaired kidney function may be affected by this medication, thus regular monitoring is necessary. Patients with impaired liver function should exercise caution, as the metabolism and excretion of this medication may be delayed. Symptoms such as dizziness, headache, hypotension, orthostatic hypotension, drowsiness, palpitation, nausea, vomiting, dyspepsia, diarrhea, skin rash, muscle pain, edema may appear during treatment; any abnormal symptoms should be discussed with a doctor. This medication is not a beta-blocker, but caution is advised upon sudden discontinuation of a beta-blocker, as risks may arise; beta-blockers should be gradually tapered off. This medication may increase blood potassium levels when taken with other antihypertensives, diuretics, potassium-sparing diuretics, or potassium supplements, and potassium levels should be frequently monitored through blood tests. Taking it with grapefruit juice may enhance the effects of the medication, so it is better to avoid this combination. It is generally advised not to use this medication during pregnancy; if planning to become pregnant, it is recommended to switch to another safe antihypertensive. In breastfeeding, this medication may pass into breast milk; thus, breastfeeding or the medication should be stopped. Safety and efficacy in pediatric patients under 18 years have not been established, so it is best not to use it in this age group. Elderly patients may have decreased liver, kidney, or cardiac function, so they should start at a low dose and be monitored closely. In case of overdose, symptoms such as hypotension, increased heart rate, and vasodilation may occur, and immediate monitoring of cardiac and respiratory function in a hospital setting is necessary for appropriate treatment. This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is also advisable to keep it out of reach of children and not to transfer it to another container.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, diminished sensation, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, pollakiuria, erectile dysfunction, peripheral edema, edema, pitting edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, low back pain, bronchitis, increased creatine phosphokinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, asthenia, angioedema, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, autoimmune hepatitis, flushing, fatigue, edema, palpitations, vertigo, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, hypotension, tachycardia, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, ideally at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Light yellow, round, film-coated tablet

Package unit

30 tablets

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.